UroGen Pharma Ltd. (URGN) Key Metrics
URGN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.69B
- Enterprise value
- $2.12B
- P/E (TTM)
- —
- Forward P/E
- 36.5
- PEG ratio
- —
- Price / sales
- 9.0 10-yr median 5.2
- Price / book
- 19.3 10-yr median 5.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.58
URGN key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsURGN valuation Price multiples at each fiscal year-end price.
Price / sales+103.2%
10.3
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+6.8 pts
−14.4%
2025 · hover or tap a bar for each year
20162025
URGN returns How much profit the business earns on the capital it uses.
Return on assets−8.5 pts
−63.1%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin−40.9 pts
−148.2%
2025 · hover or tap a bar for each year
20162025
Asset turnover+15.9%
0.45
2025 · hover or tap a bar for each year
20162025
URGN per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+8.2%
$2.28
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$3.19
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$3.38
2025 · hover or tap a bar for each year
20162025
Book value per share
−$2.19
2025 · hover or tap a bar for each year
20162025
Shares outstanding+12.2%
48.1M
2025 · hover or tap a bar for each year
20162025
URGN financial health Debt, liquidity and how easily interest is covered.
Net debt+$121.2M
$7.9M
2025 · hover or tap a bar for each year
20162025
Current ratio−33.3%
4.01
2025 · hover or tap a bar for each year
20162025
Interest coverage
-3.7
2025 · hover or tap a bar for each year
20162025
Debt / assets+48.2%
0.64
2025 · hover or tap a bar for each year
20162025
URGN efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+17 days
89 days
2025 · hover or tap a bar for each year
20162025
Days of inventory+70 days
377 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−20 days
338 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle+107 days
127 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue−0.1 pts
0.3%
2025 · hover or tap a bar for each year
20162025
URGN valuation history
Fiscal year-endToday10-year median
URGN returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
URGN debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
URGN cash returned to shareholders
DividendsBuybacksFree cash flow
URGN price vs earnings per share
Share price at year-endEPS (right axis)
URGN key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.13B | $456.6M | $432.5M | $202.3M | $212.5M | $392.5M | $685.0M | $678.4M | — | — |
| Enterprise value | $1.13B | $343.3M | $394.9M | $201.5M | $123.8M | $292.0M | $540.6M | $577.1M | — | — |
| Price / sales | 10.3 | 5.1 | 5.2 | 3.1 | 4.4 | 33.3 | — | 601.4 | — | — |
| Price / book | — | — | — | — | 25.3 | 4.1 | 3.8 | 7.5 | — | — |
| EV / sales | 10.3 | 3.8 | 4.8 | 3.1 | 2.6 | 24.7 | — | 511.6 | — | — |
| Earnings yield | −13.6% | −27.8% | −23.6% | −54.3% | −52.1% | −32.7% | −15.3% | −11.2% | — | — |
| Free cash flow yield | −14.4% | −21.3% | −17.7% | −43.4% | −40.3% | −27.3% | −10.4% | −5.6% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $23.42 | $10.65 | $15.00 | $8.87 | $9.51 | $18.02 | $33.37 | $43.06 | $37.21 | — |
| Per share | ||||||||||
| Revenue per share | $2.28 | $2.11 | $2.87 | $2.82 | $2.15 | $0.54 | $0.00 | $0.07 | — | $1.46 |
| Earnings per share | −$3.19 | −$2.96 | −$3.55 | −$4.81 | −$4.96 | −$5.90 | −$5.12 | −$4.80 | — | −$0.16 |
| Operating cash flow per share | −$3.38 | −$2.26 | −$2.65 | −$3.84 | −$3.80 | −$4.86 | −$3.46 | −$2.37 | — | $0.35 |
| Free cash flow per share | −$3.38 | −$2.26 | −$2.66 | −$3.85 | −$3.83 | −$4.92 | −$3.48 | −$2.41 | — | $0.29 |
| Cash per share | $2.50 | $5.52 | $4.75 | $4.38 | $3.99 | $4.68 | $7.16 | $6.43 | — | $1.78 |
| Book value per share | −$2.19 | −$0.21 | −$2.26 | −$3.92 | $0.38 | $4.42 | $8.78 | $5.72 | — | $1.36 |
| Tangible book value per share | −$2.19 | −$0.21 | −$2.26 | −$3.92 | $0.38 | $4.42 | $8.78 | $5.72 | — | $1.36 |
| Capex per share | $0.01 | $0.01 | $0.01 | $0.01 | $0.03 | $0.06 | $0.02 | $0.04 | — | $0.06 |
| Debt per share | $2.67 | $2.88 | $3.45 | $4.35 | $0.02 | $0.07 | $0.13 | — | — | $0.30 |
| Shares outstanding | 48.1M | 42.9M | 28.8M | 22.8M | 22.3M | 21.8M | 20.5M | 15.8M | — | 12.0M |
| Change in shares outstanding | +12.2% | +48.7% | +26.4% | +2.1% | +2.6% | +6.1% | +30.3% | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | −211.6% | −92.9% | −77.8% | −95.4% | −47.2% | −11.6% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | −703.0% | — | — | — |
| Return on assets (ROA) | −63.1% | −54.7% | −65.1% | −86.0% | −91.7% | −79.2% | −68.7% | −84.5% | −40.6% | −9.1% |
| Return on tangible assets | −76.6% | −44.4% | −57.3% | −80.9% | −92.5% | −105.3% | −52.0% | −73.1% | −26.5% | −8.4% |
| Free cash flow margin | −148.2% | −107.4% | −92.6% | −136.4% | −178.3% | −907.7% | — | — | −120.6% | 19.9% |
| Financial health | ||||||||||
| Total debt | $128.3M | $123.4M | $99.4M | $99.1M | $398,000 | $1.5M | $2.6M | — | — | $3.6M |
| Cash & short-term investments | $120.5M | $236.7M | $137.0M | $100.0M | $89.1M | $102.0M | $147.1M | $101.3M | $73.0M | $21.4M |
| Net debt | $7.9M | −$113.3M | −$37.6M | −$841,000 | −$88.7M | −$100.5M | −$144.5M | −$101.3M | −$73.0M | −$17.8M |
| Debt / equity | — | — | — | — | 0.05 | 0.02 | 0.01 | — | — | 0.22 |
| Debt / assets | 0.64 | 0.43 | 0.56 | 0.73 | 0.00 | 0.01 | 0.01 | — | — | 0.16 |
| Net debt / EBITDA | — | — | — | — | — | — | — | — | — | −17.56 |
| Current ratio | 4.01 | 6.01 | 5.42 | 5.39 | 5.11 | 5.39 | 7.63 | 7.59 | 10.59 | 7.03 |
| Quick ratio | 3.65 | 5.81 | 5.24 | 5.21 | 4.90 | 5.30 | 7.63 | 7.59 | 10.54 | 6.99 |
| Interest coverage | -3.7 | -7.7 | -4.5 | -9.4 | -5.3 | -34.5 | -385.5 | — | — | — |
| Working capital | $139.6M | $230.2M | $138.0M | $105.0M | $92.0M | $94.2M | $129.2M | $88.8M | $67.4M | $18.9M |
| Invested capital | −$97.6M | −$122.1M | −$102.8M | −$90.2M | −$80.3M | −$4.2M | $35.8M | −$11.2M | −$4.5M | −$1.4M |
| Tangible asset value | −$105.5M | −$8.8M | −$65.2M | −$89.4M | $8.4M | $96.4M | $180.3M | $90.1M | $68.5M | $16.3M |
| Net current asset value | −$119.9M | −$18.4M | −$74.3M | −$96.1M | $3.1M | $90.0M | $126.5M | $88.8M | $67.4M | $15.3M |
| Graham net-net per share | −$3.17 | −$0.89 | −$3.20 | −$4.97 | −$0.49 | $3.79 | $6.09 | $5.58 | — | $1.23 |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | $0 | $83,000 | $0 | $0 | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | — | — | 0.0% |
| Capex / revenue | 0.3% | 0.3% | 0.2% | 0.4% | 1.6% | 10.3% | 1,805.6% | 49.6% | 3.3% | 4.0% |
| Capex / operating cash flow | — | — | — | — | — | — | — | — | — | 16.6% |
| Capex / depreciation | 0.12 | 0.25 | 0.11 | 0.14 | 0.42 | 0.59 | 0.25 | 1.34 | 1.31 | 3.26 |
| Stock-based compensation / revenue | 10.9% | 14.5% | 11.3% | 16.4% | 48.1% | 237.5% | 166,483.3% | 2,716.5% | 77.2% | 11.2% |
| R&D / revenue | 61.1% | 63.2% | 55.1% | 82.2% | 99.2% | 401.0% | 273,872.2% | 3,274.3% | 229.2% | 58.7% |
| SG&A / revenue | 141.3% | 134.0% | 109.2% | 128.7% | 182.2% | 764.6% | 334,438.9% | 3,508.1% | 108.0% | 36.6% |
| Efficiency | ||||||||||
| Days sales outstanding | 88.7 | 72.2 | 62.1 | 69.3 | 71.3 | 218.0 | — | — | 6.3 | 1.7 |
| Days of inventory on hand | 376.7 | 306.2 | 194.9 | 218.3 | 240.5 | 710.5 | — | — | 128.1 | 1,368.8 |
| Days payables outstanding | 338.2 | 358.5 | 234.7 | 269.7 | 320.5 | 1,440.6 | 34,089.5 | 719.8 | 1,435.4 | 23,438.2 |
| Cash conversion cycle (days) | 127.2 | 19.9 | 22.3 | 17.8 | -8.7 | -512.2 | — | — | -1,301.0 | -22,067.7 |
| Receivables turnover | 4.11 | 5.06 | 5.88 | 5.27 | 5.12 | 1.67 | — | — | 58.06 | 211.20 |
| Payables turnover | 1.08 | 1.02 | 1.55 | 1.35 | 1.14 | 0.25 | 0.01 | 0.51 | 0.25 | 0.02 |
| Inventory turnover | 0.97 | 1.19 | 1.87 | 1.67 | 1.52 | 0.51 | — | — | 2.85 | 0.27 |
| Asset turnover | 0.45 | 0.39 | 0.53 | 0.50 | 0.40 | 0.07 | 0.00 | 0.01 | 0.17 | 0.83 |
| Average receivables | $26.7M | $17.9M | $14.1M | $12.2M | $9.4M | $7.0M | — | — | $140,500 | $83,000 |
| Average payables | $11.5M | $8.7M | $6.0M | $5.7M | $4.5M | $4.0M | $4.5M | $3.6M | $2.4M | $1.8M |
| Average inventory | $12.8M | $7.5M | $5.0M | $4.6M | $3.4M | $2.0M | — | — | $210,500 | $105,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from URGN's annual financial statements (latest annual report filed March 2, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
URGN valuation and financial ratios
It ended the year with $128.3 million of debt and $120.5 million in cash and short-term investments, net debt of $7.9 million. The share count rose 301.9% from 12.0M to 48.1M over 9 years.
See the URGN income statement, the URGN chart for price history, or the URGN stock overview for the latest quote and news.
URGN key metrics FAQ
How much debt does UroGen Pharma have?
UroGen Pharma had total debt of $128.3 million at the end of fiscal 2025.
What is UroGen Pharma's free cash flow yield?
UroGen Pharma generated -$162.7 million of free cash flow in fiscal 2025, a free cash flow yield of −14.4% on its market value at year-end ($1.1 billion).
What is UroGen Pharma's current ratio?
UroGen Pharma's current ratio was 4.01 at the end of fiscal 2025: current assets were 4.01 times current liabilities.